Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Updates from ASCO 2024 in gastrointestinal tumours

Best of ASCO® 2024 Miami Symposium

12 - 13 Jul 2024

Published: 12 Jul 2024

Views: 52

Rating:

Save

Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, USA

Dr Samuel Kareff, speaks to ecancer at the Best of ASCO®️ 2024 Miami Symposium about the updates from ASCO 2024 discussed in a panel for gastrointestinal tumours.

He first highlights the ESOPEC trial which showed that perioperative FLOT was superior in overall and progression free survival to neoadjuvant chemoradiation for oesophageal adenocarcinoma.

Dr Kareff then discusses the next steps for gastrointestinal tumours touching on an over reliance on ctDNA guidance of adjuvant therapy for locally advanced colorectal tumours and hoping for more progress in other tumour types.

Related Videos

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Multiple Myeloma: evolving paradigm - Panel Discussion

Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr...

Multiple Myeloma: evolving paradigm - Panel Discussion ( Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2...

Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer ( Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy )

Multiple myeloma (A cancer arising from plasma cells)

Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal

Multiple myeloma (A cancer arising from plasma cells) ( Dr Nikesh Bajracharya - Civil Service Hospital, Kathmandu, Nepal )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

More from ecancer